Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C-Reference-Cited by-同舟云学术

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C

Published:2021-05-15 Issue:3 Volume:15 Page:327-328
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Lee Chang Hun¹^ORCID,Kim In Hee¹^ORCID

Affiliation:

1. Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

https://pdf.medrang.co.kr/GNL/2021/015/GNL015-03-327.pdf

Reference10 articles.

1. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

2. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

3. Decreased risk of hepatocellular carcinoma recurrence with directacting antivirals compared with no treatment for hepatitis C: a meta-analysis

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC

5. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal;Hepatoma Research;2023